Toggle menu
Toggle preferences menu
Toggle personal menu
Not logged in
Your IP address will be publicly visible if you make any edits.
(Redirected from Orap)
Antipsychotic, Neuroleptic
Pimozide
Orap

Experience

👥 No personal reports yet
No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Interactions

Pharmacogenomic + mechanism interactions2 edges
Pharmacogenomic guideline recommendationsCPIC and Dutch Pharmacogenetics Working Group clinical guidelines
Phenotype:CYP2D6 poor metabolizer dose reduce 50 DPWG 60 / 100
DPWG guideline: Patients who are CYP2D6 intermediate metabolizers should be given no more than 80% of the standard maximum dose of pimozide while patients who are CYP2D6 poor metabolizers should be given no more than 50% of the standard maximum dose.
Phenotype:CYP2D6 intermediate metabolizer dose reduce 50 DPWG 60 / 100
DPWG guideline: Patients who are CYP2D6 intermediate metabolizers should be given no more than 80% of the standard maximum dose of pimozide while patients who are CYP2D6 poor metabolizers should be given no more than 50% of the standard maximum dose.

Patient experience

No patient-experience reports yet.

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Summary
Classes
Antipsychotic, Neuroleptic
Pharmacy
Pharmacology
Purported mechanism
Diphenylbutylpiperidine D2 antagonist